Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00234299 · ClinicalTrials.gov registry record · NA
Effects of ASA on Prostate Tissue
A NA study, sponsored by University of Washington.
- Completed
- Registry status
- NA
- Development phase
- 60
- Enrollment target
NCT00234299 is a NA study that has completed, run by University of Washington. The registered enrollment target is 60 participants.
The verdict
NCT00234299, a NA study, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- NA
- Development phase
- 60 participants
- Enrollment target
Study Summary
Aspirin affects many physiological processes through its anti-inflammatory actions. Various cancers, including prostate cancer, appear to utilize inflammatory signals to facilitate their growth and progression. We hypothesize that oral aspirin acts directly on prostate epithelial cells to alter COX-2-related metabolism and inhibit prostate cell growth.
Interventions
- DRUG Placebo
- DRUG Aspirin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2005-12 |
| Est. Completion | 2015-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00234299
The ClinicalTrials.gov registry entry for NCT00234299 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00234299 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00234299 about?
NCT00234299 is a clinical study titled "Effects of ASA on Prostate Tissue". Aspirin affects many physiological processes through its anti-inflammatory actions. Various cancers, including prostate cancer, appear to utilize inflammatory signals to facilitate their growth and progression. We hypothesize that oral aspirin acts directly on prostate epithelial cells to alter COX...
What is the current status of trial NCT00234299?
This trial is currently completed. It is a NA study. The enrollment target is 60 participants. The study started on 2005-12. Estimated completion is 2015-12.
What interventions are being tested in trial NCT00234299?
The interventions under investigation include: Placebo (DRUG), Aspirin (DRUG).
Who is sponsoring clinical trial NCT00234299?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.